Clovis Oncology (CLVS) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Clovis Oncology Announces Second Quarter 2015 Operating Results
August 6, 2015 4:00 PM EDTCompleted rociletinib (CO-1686) U.S. NDA and E.U. MAA regulatory submissions in July for patients with EGFR-mutant non-small cell lung cancer who have been previously treated with an EGFR-targeted therapy and have the T790M mutation Preparing for potential Q4 2015 U.S. launch of rociletinib; establishing European commercial organization for potential 2016 launch of rociletinib Raised $298 million in July equity offering; June 30, 2015 pro forma cash and available-for-sale securities balance of $676 million
BOULDER, Colo.--(BUSINESS WIRE)--... More
